{"id":"W1997853067","doi":"10.1007/s10637-007-9097-9","title":"A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Queen's University; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Melanoma; Neutropenia; Adverse effect; Toxicity; Clinical trial; Internal medicine; Phases of clinical research; Cancer; Pharmacokinetics; Chemotherapy; Surgery; Oncology; Gastroenterology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00174959,0.002220548,0.002702572,0.0004334063,0.0006514749,0.001235781,0.001092705,0.001765817,0.005170634],"category_scores_gemma":[0.0009803823,0.000632295,0.001929108,0.0005635969,0.001114266,0.0008439352,0.0003532755,0.004367909,0.001359885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00189869,"about_ca_system_score_gemma":0.003026289,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008539056,"about_ca_topic_score_gemma":0.02707331,"domain_scores_codex":[0.9995149,0.000223639,0.00001381872,0.00006749987,0.00004282479,0.0001373809],"domain_scores_gemma":[0.9991818,0.00008904144,0.0001162206,0.00005223107,0.00005251141,0.0005081634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8258075,0.02431648,0.005841695,0.001227849,0.002430946,0.0003746024,0.000266931,0.002809132,0.0182026,0.0005659271,0.01643769,0.1017186],"study_design_scores_gemma":[0.8363798,0.1476073,0.00854144,0.0000514484,0.0006358831,0.0002597553,0.00006775818,0.0009842357,0.001013774,0.0002543578,0.004167975,0.00003624082],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9746298,0.007309091,0.0006814944,0.002418208,0.0005669715,0.003438944,0.003807678,0.0001820801,0.006965789],"genre_scores_gemma":[0.9724955,0.005933739,0.001721763,0.002633131,0.0004425647,0.00262513,0.005777352,0.00006185903,0.008309139],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9914609,"threshold_uncertainty_score":0.01729751,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08669226906530368,"score_gpt":0.3826761406183515,"score_spread":0.2959838715530478,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}